ISSN: 1080-6059
Laetitia Ninove, Philippe Parola, Cécile Baronti, Xavier De
Lamballerie, Philippe Gautret, Barbara Doudier, and Rémi N. Charrel ![]()
Author affiliation: Fédération de Microbiologie Clinique
Assistance Publique Hôpitaux de Marseille, Marseille, France
Suggested citation for this article
To the Editor: GeoSentinel, the global surveillance program of the International Society of Travel Medicine, recently reported that returning travelers may serve as sentinels for local outbreaks of dengue fever in tropical areas to which it is endemic (1). We investigated a case of dengue virus (DENV) type 3 (DENV-3) infection in a traveler returning to France from West Africa, which provided evidence for DENV-3 circulation in Côte d'Ivoire.
A 53-year-old French expatriate living in Abidjan, the economic capital of Côte d'Ivoire, arrived in France on July 17, 2008, and was hospitalized 4 days later with fever of 40°C, headache, asthenia, anorexia, chills, diffuse arthralgia, and myalgia. Results of a physical examination were normal except for a diffuse nonpetechial macular rash and moderate hepatosplenomegaly. A tourniquet test was not performed. At admission, platelet count was 103 cells/mm3 and leukocyte count was 2,410 cells/mm3. Thin and thick blood smears and results of the immunochromatographic test (Binax NOW malaria tests; Binax, Portland, ME, USA) were negative. The patient recovered without sequelae and was discharged 6 days after admission.
At admission, chikungunya virus–specific immunoglobulin (Ig) G and IgM were not detected by indirect immunofluorescence tests (2). IgG, but not IgM, specific for DENV was detected by an immunochromatic test (Panbio Dengue Duo Cassette; Biotrin, Lyon, France) and confirmed by ELISA (PanBio dengue duo test). However, DENV RNA was demonstrated in serum by using 4 reverse-transcription–PCR (RT-PCR)–based assays: a positive result in a flavivirus universal assay (3), a positive result in a DENV-1–4 real-time RT-PCR (4), a positive result in a DENV-3–specific RT-PCR, and a negative result in a specific RT-PCR for DENV-1, -2, and -4 (4). The concomitant finding of DENV RNA and IgG against DENV suggests the patient had dengue infection before this episode.
![]() |
Figure. Phylogenetic analysis of selected dengue virus type 3 (DENV-3) sequences... |
DENV-3 viremia was confirmed by sequencing a 547-nt region of the envelope gene (GenBank accession no. FJ587232, nt 852–1398 referring to the H87 DENV-3 prototype strain). Our sequence aligned with homologous DENV-3 sequences retrieved from GenBank and used for phylogenetic analysis (Figure). Our patient, in whom classic dengue fever was diagnosed, was infected with a strain that belonged to genotype III most closely related to strains isolated in Singapore, Taiwan, Sri Lanka, India, and Saudi Arabia. Its closest relatives were the strain from Saudi Arabia isolated in 2004 and another strain claimed in ProMED by Japanese researchers to have been isolated in 2008 from a Japanese traveler returning from Côte d'Ivoire (6). Therefore, this strain is likely to have originated in the Middle East, the Indian subcontinent, or Southeast Asia rather than in Central or South America.
In Africa, most data on epidemic or endemic dengue activity originate in East Africa. Dengue fever was seldom reported in West Africa. In 2000, DENV-1 was isolated from a French soldier in Côte d'Ivoire (7). More recently, an outbreak caused by DENV-2 occurred in Gabon in West Africa (8). In this context, it is notable that DENV-3 strains recently caused unexpected outbreaks of dengue hemorrhagic fever in Sri Lanka, East Africa, and Latin America (9).
The case presented here demonstrates that epidemics may be undetected or unidentified until diagnosis is assessed in another country from a returning infected visitor, thus drawing attention to an unidentified potential epidemic situation. This situation can be unraveled by a clinician who considers geographic factors in the diagnostic workup and has access to and uses appropriate laboratory capacity to diagnose imported infections. At the time dengue was diagnosed in this patient, cases of yellow fever were reported in the same location of Côte d'Ivoire (Abidjan) (5), illustrating concomitant circulation of 2 viruses in which dengue may have remained undetected in the absence of a laboratory-confirmed case in the traveler's home country. Therefore, this case reinforces the utility of travelers as sentinels for infectious diseases as previously reported (10). Our findings reiterate the need for technologic transfer of PCR-based direct diagnostics to reference centers in areas where emergence is likely. These efforts also should embrace serology and encourage close collaboration with world reference centers for confirmation and characterization (10).
We thank David Freedman, EuroTravNet members, and the reviewers for helpful comments and discussion.
Figure. Phylogenetic analysis of selected dengue virus type 3 (DENV-3) sequences...
Ninove L, Parola P, Baronti C, de Lamballerie X, Gautret P, Doudier B, et al. Dengue virus type 3 infection in traveler returning from West Africa [letter]. Emerg Infect Dis [serial on the Internet]. 2009 Nov [date cited]. Available from http://www.cdc.gov/EID/content/15/11/1871.htm
DOI: 10.3201/eid1511.081736
Please use the form below to submit correspondence to the authors or contact them at the following address:
Rémi N. Charrel, Université de la Mediterranee–Unite des Virus Emergents, 27 bd Jean Moulin, Marseille 13005, France; email: rnc-virophdm@gulliver.fr
Contact us at eideditor@cdc.gov
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
This page posted October 23, 2009
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Tel: (404) 639-3311 / Public Inquiries: (404) 639-3534 / (800) 311-3435